1. A 28-year-old woman in the third trimester of pregnancy collapses at home. Her husband calls emergency services. On EMS arrival, she is supine, unresponsive, BP 72/44 mmHg, heart rate 138 bpm, SpO2 88% on room air. EMS notes she is in her third trimester with a gravid uterus. Which of the following most accurately explains the autonomic mechanism of hypotension in a supine pregnant patient and the correct immediate intervention?

• A) The hypotension reflects aortocaval compression syndrome -- in the supine position, the gravid uterus compresses the inferior vena cava (reducing venous return to the right heart, reducing preload and cardiac output) and may compress the aorta (reducing perfusion pressure); the compensatory sympathetic response (baroreceptor-mediated tachycardia and vasoconstriction) is overwhelmed by the mechanical obstruction; the correct immediate intervention is left lateral decubitus positioning (15-30 degree left tilt) or manual left uterine displacement -- mechanically decompressing the IVC restores venous return and cardiac output, correcting the hypotension through a purely mechanical mechanism; pharmacological vasopressors alone without positional correction will not fully restore hemodynamics and may reduce uteroplacental perfusion without improving maternal cardiac output.
• B) The hypotension in third-trimester supine positioning is caused by parasympathetic vasovagal reflex activation triggered by uterine contractions pressing on the cervix -- the cervical stretch activates vagal afferents in the pelvic parasympathetic nerves which synapse in the NTS, increasing vagal M2 tone at the SA node and producing M3-mediated vasodilation at peripheral resistance vessels; atropine corrects this by blocking M2 and M3 receptors, reversing both the bradycardia and the vasodilation.
• C) Supine hypotension of pregnancy results from progesterone-mediated downregulation of alpha-1 adrenergic receptors in vascular smooth muscle -- progesterone in high concentrations blocks alpha-1 receptor coupling to Gq, reducing the vasoconstrictive response to NE; vasopressors that depend on alpha-1 receptor activation (phenylephrine, norepinephrine) are ineffective in pregnancy because of progesterone-mediated alpha-1 downregulation; ephedrine is therefore the preferred vasopressor in obstetric settings.
• D) The clinical picture reflects amniotic fluid embolism -- the sudden cardiovascular collapse in late pregnancy is caused by amniotic fluid entering the maternal pulmonary circulation via uterine veins, producing acute right heart failure and anaphylactoid complement activation; the supine position is not relevant to this diagnosis; treatment requires immediate cardiopulmonary support with IV epinephrine for the anaphylactoid component, and emergent caesarean section to reduce right ventricular afterload.

2. A 72-year-old man with heart failure with reduced ejection fraction (EF 28%), complete heart block requiring a dual-chamber pacemaker, and hypertension is found unresponsive at home. His wife reports he took a handful of his medications an hour ago in what she describes as a suicide attempt. His medication bottles include metoprolol succinate 200 mg, diltiazem 360 mg extended-release, digoxin 0.25 mg, and lisinopril. On arrival: BP 64/38 mmHg, heart rate 28 bpm (pacemaker-paced but not capturing), GCS 8, glucose 88 mg/dL. ECG shows complete AV block with pacemaker spikes not followed by QRS complexes. Which of the following most accurately identifies the pharmacological mechanisms of the life-threatening cardiovascular toxicity and guides initial resuscitative management?

• A) The combined overdose produces multi-drug cardiovascular toxicity: metoprolol (beta-1 antagonist) blocks beta-1 receptors at the SA and AV nodes; diltiazem (non-dihydropyridine CCB) blocks L-type calcium channels at the SA and AV nodes; digoxin inhibits Na+/K+-ATPase and enhances vagotonic AV nodal inhibition -- all three drugs additively suppress AV conduction; lisinopril (ACE inhibitor) produces hypotension through vasodilation without direct cardiac conduction effects; pacemaker failure to capture reflects myocardial calcium channel blockade from diltiazem impairing action potential conduction to the myocardium even when pacemaker current is delivered; initial management: high-dose insulin euglycemic therapy (HIET -- most evidence-based treatment for CCB and BB poisoning), calcium chloride IV (overcomes diltiazem calcium channel blockade), glucagon IV (activates Gs-cAMP on cardiac cells independent of the beta-1 pathway), digoxin-specific Fab fragments (Digibind), vasopressors, transcutaneous pacing.
• B) The primary life-threatening toxicity is from lisinopril -- ACE inhibitors in overdose produce complete AV block by accumulating angiotensin II in cardiac conduction tissue, which directly blocks L-type calcium channels; the correct management is IV angiotensin II infusion (Giapreza) to restore angiotensin-mediated calcium channel function and high-dose atropine for the AV block.
• C) The pacemaker failure to capture indicates the myocardium is in electrical-mechanical dissociation from digoxin toxicity -- the correct antidote is digoxin-specific antibody fragments (Digibind/DigiFab) alone; all other interventions including calcium are contraindicated in digoxin toxicity because they worsen intracellular calcium overload.
• D) The combination of metoprolol, diltiazem, and digoxin produces synergistic AV nodal conduction suppression: beta-1 blockade reduces cAMP-driven L-type calcium channel availability; diltiazem directly blocks the same L-type calcium channels; digoxin inhibits Na+/K+-ATPase raising intracellular sodium which reduces NCX-mediated calcium extrusion and enhances vagotonic AV nodal inhibition -- three complementary mechanisms producing complete conduction block; pacemaker failure to capture reflects diltiazem-induced calcium channel blockade in ventricular myocardium impairing action potential generation even when pacemaker current is delivered; management priorities: IV calcium chloride (most urgent -- partially reverses diltiazem blockade and may restore pacemaker capture); high-dose regular insulin plus glucose (HIET for CCB and BB poisoning -- improves cardiac contractility by shifting myocardial metabolism to glucose); IV glucagon (bypasses beta-1 blockade via Gs-cAMP); digoxin Fab fragments; vasopressors for persistent hypotension; ECMO if pharmacological measures fail.

3. A 19-year-old college student is brought to the emergency department by friends who found him agitated and confused at a party. He is tachycardic (HR 148 bpm), hyperthermic (temperature 40.2 degrees Celsius), diaphoretic, and has bilateral dilated pupils (8 mm). His friends report he took ecstasy (MDMA). Which of the following most accurately explains the complete autonomic and serotonergic mechanism of MDMA toxicity and identifies the life-threatening complication most likely to cause death?

• A) MDMA produces toxicity exclusively through alpha-1 adrenergic receptor activation -- MDMA is a selective alpha-1 agonist that produces hypertension, tachycardia, hyperthermia, and mydriasis through direct alpha-1 receptor binding; the serotonin syndrome component is a pharmacological myth; treatment is phentolamine (alpha-1 blocker) to reverse all of the cardiovascular manifestations; diaphoresis is paradoxical for an alpha-1 agonist and reflects secondary parasympathetic activation.
• B) MDMA (3,4-methylenedioxymethamphetamine) is an indirect sympathomimetic and serotonin-releasing agent: (1) MDMA enters serotonergic nerve terminals via SERT, reverses SERT transport direction (efflux mode), and massively releases serotonin from vesicular and cytoplasmic stores -- producing the serotonergic features; MDMA also inhibits MAO-A and reverses VMAT2; (2) MDMA similarly enters dopaminergic and noradrenergic terminals via DAT and NET, releasing dopamine and NE by efflux -- producing sympathomimetic features (tachycardia from beta-1, hypertension and mydriasis from alpha-1, hyperthermia from combined sympathomimesis and serotonin-mediated hypothalamic temperature dysregulation); (3) The life-threatening complication most likely to cause death is hyperthermia complicated by rhabdomyolysis, disseminated intravascular coagulation, and multi-organ failure -- particularly in a hot, crowded environment where physical exertion, ambient heat, and dehydration compound MDMA-induced thermogenic drive; (4) Hyponatremia from SIADH (MDMA stimulates ADH release via serotonergic hypothalamic pathways and users often drink excessive water) is the second most common cause of death in young MDMA users, particularly women; treatment priorities: active cooling, benzodiazepines (reduce psychomotor agitation-generated heat and treat seizures), cyproheptadine for serotonin syndrome features.
• C) MDMA toxicity is identical to serotonin syndrome from SSRI-MAOI combination -- MDMA acts only as a potent MAOI producing serotonin accumulation from impaired degradation without any direct transporter-reversing or releasing mechanism; treatment is cyproheptadine (5-HT2A antagonist) alone; sympathomimetic features are epiphenomena of serotonin excess at peripheral 5-HT2A receptors on vascular smooth muscle.
• D) The most life-threatening complication of MDMA toxicity is acute hypertensive intracranial hemorrhage -- the alpha-1 receptor-mediated hypertension from MDMA is the primary killer; hyperthermia, rhabdomyolysis, and DIC are secondary to the hypertension and resolve with blood pressure control; cyproheptadine is contraindicated in MDMA toxicity.

4. A 56-year-old woman with depression treated with venlafaxine (SNRI: blocks SERT and NET) presents requesting treatment for stress urinary incontinence. Her physician considers duloxetine. Which of the following most accurately explains the receptor mechanism by which duloxetine treats stress urinary incontinence and identifies the relevant pharmacological interaction with her existing venlafaxine therapy?

• A) Duloxetine treats stress urinary incontinence by blocking muscarinic M3 receptors on the detrusor muscle, reducing uninhibited detrusor contractions during physical exertion -- the mechanism is identical to oxybutynin; the pharmacological interaction with venlafaxine is additive M3 blockade producing enhanced anticholinergic effects including dry mouth, constipation, and urinary retention.
• B) Duloxetine treats stress urinary incontinence through dual NET and SERT inhibition in the sacral spinal cord (Onuf nucleus — a discrete cluster of somatic alpha-motor neurons in the anterior horn at S2-S4 that innervate the external urethral and anal sphincters via the pudendal nerve) -- pudendal motor neurons in Onuf nucleus at S2-S4 receive excitatory noradrenergic (via alpha-1A receptors) and serotonergic (via 5-HT2 receptors) input from descending brainstem projections; duloxetine inhibiting NET and SERT in these descending pathway synapses onto Onuf nucleus motor neurons increases norepinephrine and serotonin concentrations at the pudendal motor neuron synapse, increasing external urethral sphincter (rhabdosphincter) tone via enhanced alpha-1A noradrenergic and 5-HT2 serotonergic excitation -- increasing maximum urethral closure pressure during sudden abdominal pressure rises (coughing, sneezing, exercise), reducing urine leakage; pharmacological interaction with venlafaxine: both are NET and SERT inhibitors; combining them would produce additive serotonin and norepinephrine reuptake inhibition with significant risk of serotonin syndrome (excess synaptic serotonin at 5-HT1A and 5-HT2A receptors producing the Hunter triad of neuromuscular abnormalities, autonomic instability, and altered mental status); they should NOT be co-administered; venlafaxine itself may provide sufficient Onuf nucleus noradrenergic and serotonergic tone to treat mild stress incontinence.
• C) Duloxetine treats stress urinary incontinence through selective alpha-1A adrenergic receptor agonism at the internal urethral sphincter smooth muscle -- it directly activates alpha-1A receptors to increase internal sphincter tone during exertion; the pharmacological interaction with venlafaxine is pharmacokinetic (venlafaxine inhibits CYP2D6, increasing duloxetine plasma levels by approximately 3-fold and requiring dose reduction).
• D) Duloxetine has no FDA approval for urinary stress incontinence in the United States -- the physician should instead prescribe mirabegron; mirabegron beta-3 receptor activation on the detrusor produces relaxation during filling, indirectly increasing urethral closure pressure; venlafaxine has no pharmacological interaction with mirabegron.